"The U.S. Food and Drug Administration on Wednesday approved a request by Danco Laboratories to expand authorized use of its abortion pill Mifeprex (mifepristone), formerly known as RU-486, to 70 days of gestation from 49 days.
Symptoms of oral contraceptive overdosage in adults and children may include nausea, vomiting, and drowsiness/fatigue; withdrawal bleeding may occur in females. There is no specific antidote and further treatment of overdose, if necessary, is directed to the symptoms.
NONCONTRACEPTIVE HEALTH BENEFITS
The following noncontraceptive health benefits related to the use of oral contraceptives are supported by epidemiological studies which largely utilized oral-contraceptive formulations containing doses exceeding 0.035 mg of ethinyl estradiol or 0.05 mg of mestranol.
Effects on menses:
Increased menstrual cycle regularity
Decreased incidence of dysmenorrhea
Effects related to inhibition of ovulation:
Decreased incidence of ectopic pregnancies
Effects from long-term use:
Decreased incidence of fibroadenomas and fibrocystic disease of the breast
Decreased incidence of endometrial cancer
Decreased incidence of ovarian cancer
Combination oral contraceptives should not be used in women with any of the following conditions:
This monograph has been modified to include the generic and brand name in many instances.
Thrombophlebitis or thromboembolic disorders
A past history of deep-vein thrombophlebitis or thromboembolic disorders
Thrombogenic rhythm disorders
Known or suspected pregnancy
Hypersensitivity to any of the components of Alesse (levonorgestrel and ethinyl estradiol)
Last reviewed on RxList: 1/9/2005
Additional Alesse Information
Lutera - User Reviews
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.